Advances in Antiviral Drug Design Ebook

Publication: Elsevier Science
 
Is my Device Supported?


Sorry, this ebook is not available for sale. Please take a look at other works by author, or good alternatives from the same category.

Description

(E-Books do not include any DVD or CD with the purchase.)

Volume 3 of Advances in Antiviral Drug Design is keeping up with the recent progress made in the field of antiviral drug research and highlights five specific directions that have opened new avenues for the treatment of virus infections.
First , the use of lamivudine (3TC) for the treatment of HIV infections, and its more recent introduction for the treatment of hepatitis B virus (HBV) infections, has heralded the transition of D- to L-nucleosides in the antiviral nucleoside drug design, and it is likely that the future will provide more nucleosides of the L-configuration, such as (-)FFC (emtricitabine) and L-FMAU, as will be described by J.-C.G. Graciet and R.F. Shinazi.
_ Second_ , the acyclic purine nucleoside phosphonates, i.e. PMEA (adefovir and PMPA (tenofovir), offer great potential as both anti-HIV and anti-HBV agents, and both compounds have been the subject of advanced clinical trials in their oral produrg form (adefovir dipivoxil and tenofovir disoproxyl), as mentioned by M.N. Arimilli, J.P. Dougherty, K.C. Cundy, and N. Bischofberger.
Third , with the advent of nevirapine, delavirdine, and efavirenz, the NNRTIs have definitely come of age. Emivirine (MKC-442), a derivative of the original HEPT analog that was described in 1989 has now proceeded through pivotal clinical studies, and how this class of compounds evolved is presented in the account of H. Tanaka and his colleagues.
_ Fourth_ , at the end of 1999, anticipating on the next winter influenza offensive, we should have at end two compounds that specifically inhibit influenza A and B virus infections: zanamivir (by the intranasal route) and oseltamivir (by the oral route). Both compounds have proved effective in the prophylaxis and treatment of influenza A and B virus infections and act through the same mechanism; that is by blocking the viral neuraminidase (or sialidase), a key enzyme that allows the virus to spread from one cell to another (within the respiratory mucosal tract). The design of these sialidase inhibitors will be presented by M. von Itzstein and J.C. Dyason.
Fifth , the discovery (in 1996) of the chemokine receptors CXCR4 and CCR5 as essential coreceptors (in addition to the CD4 receptor) for HIV entry into the cells, has boosted an enormous interest in potential antagonists of these receptors. The bicyclams represent the first low-molecular-weight compounds targeted at CXCR4, the coreceptor used by the more pathogenic, T-lymphotropic, HIV strains, to enter the cells. They will be addressed by G.J. Bridger and R.T. Skerlj.
The five topics covered in this third volume of _ Advances in_ Antiviral Drug Design are in the front line of the present endeavors towards the chemotherapy of virus infections. They pertain to the combat against three of the most important virus infections of current times: HIV, HBV, and influenza virus.

Should you buy this Ebook?

We've put together a collection of resources to help you make a decision regarding whether you should buy this Ebook from us.

  1. Is your device one of these? Ebook reading software will work on the following devices: Windows, Mac, Android 2.2+ Devices, IPad (iOS 3+), IPhone (iOS 3+), Kindle Fire. Several other devices are also supported by the software.
  2. Compare prices. Our price is $125.00. If you would like to research our competitors to see their prices. Here're some places to look:
  3. Why should you buy Ebooks from onlinebookplace.com?

    We've had 1000s of downloads so far and with over 300000+ Ebooks to choose from, onlinebookplace.com is becoming a favorite Ebook Store for many. Allow us to win you over with our competitive pricing, upfront policies and diligent customer service.

    We're Upfront:

    • Every Ebook page on onlinebookplace.com has information on restrictions that publishers have placed on the Ebook along with a clear indication of software required to read the Ebooks.
    • If ratings for an Ebook are available from one of several sources online, then we've attempted to get those to help you make a better purchasing decision about the Ebook. Reviews from Goodreads (a popular reviews site) are provided on the same if they're available.
    • In most cases, we've also attempted to get you links to the Ebook on our competitor's site so that you can compare prices with relative ease.
    • We use McAfee to scan for any vulnerabilities in the system to ensure that any information that you give us does not fall into the wrong hands.
    • We use Paypal, a trusted 3rd party payment provider to accept Payments -- your payment information doen't reside with us. Any information that does end up with us is safe.

Check below for device compatibility and any free 3rd-party software requirements. Choice of what ebook reading app to use is yours, we only present a few common apps that several customers of ours have preferred. You should be able to transfer your purchase to more than one (upto 6) compatible devices as long as your ebook-reading apps have been registered with the same Adobe ID before opening the file.

Computers/laptops/Mac

Windows/Mac PC or Laptop

Free app Adobe Reader required.

Android

Android 2.1+

Most Android devices already have ability to open this format. In case your hardware doesn't, then Adobe Reader may need to be installed.

Kindle Fire (and any Android based Kindle models)

Kindle Should be able to open this format natively.

IPhone/IPad

IPad or IPhone

Most iPhone/iPad devices may already have ability to open this format. In case your hardware doesn't, then Adobe Reader may need to be installed.

Other E-Reader

Several Other devices supported

Most iPhone/iPad devices may already have ability to open PDF or EPub this format. Please refer to your device's documentation to ensure that there is support.

Advances in Antiviral Drug Design